Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders

• The firm added that the price per share represents a 22% premium over the stock’s closing price on March 3, 2026.
• The transaction is expected to close in the second half of 2026.
• On March 3, the company announced the topline results of its phase 3 CYPRESS study, which did not meet its primary end point.

Shares of Theravance Biopharma, Inc. (TBPH) were under pressure in premarket trading on Monday after the company announced that Zymeworks will buy the pharma major for $17.00 per share in cash.

At the time of writing, TBPH stock was down over 2.5% on Monday.

Contours Of The Deal

Theravance Biopharma stated that the deal's equity value totals $929 million. Theravance shareholders will receive a contingent value right (CVR) under which they will get 80% of net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years. The remaining 20% of the proceeds will be allocated to Zymeworks, the company said.

The firm added that the price per share represents a 22% premium over the stock’s closing price on March 3, 2026. It also represents a 10% premium to its volume-weighted average price since that date.

"After evaluating a broad range of strategic alternatives, the Strategic Review Committee and full Board of Directors determined that this transaction achieves the greatest value for Theravance Biopharma shareholders," said Susannah Gray, independent Chair of the Board and Chair of the Strategic Review Committee. “This transaction also preserves the opportunity for them to benefit from any future value that may be realized from ampreloxetine through the contingent value right."

The company said that the Strategic Review Committee, consisting of independent directors, recommended this transaction to the board. The deal is expected to conclude in the second half of 2026.

Theravance Biopharma’s Phase 3 CYPRESS Study

On March 3, the company announced the topline results of its phase 3 CYPRESS study, which did not meet its primary endpoint. As a result, the company decided to wrap up its ampreloxetine program. 

The phase 3 study aimed to evaluate the efficacy and safety of ampreloxetine in patients with a rare condition called multiple system atrophy (MSA), which causes a sudden drop in blood pressure when standing up.

What Retail Thinks Of TBPH

On Stocktwits, retail sentiment surrounding the stock has remained ‘neutral’ amid ‘high’ message volumes in the past 24 hours.

TBPH stock has dropped over 2% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: Dan Ives Says MSFT, ORCL Are 'Way Oversold', Expects A Reversal In Next 6-9 Months